Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04214860
Title APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Aprea Therapeutics AB
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Yale Cancer Center New Haven Connecticut 06511 United States Details
H. Lee Moffitt CC Tampa Florida 33612 United States Details
Northwestern Medicine Chicago Illinois 60611 United States Details
University of Chicago Medicine Chicago Illinois 60637 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Weill Cornell Cancer Center New York New York 10021 United States Details
Memorial Sloan Kettering CC New York New York 10065 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from for the field